Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with Reduced CNI in Pediatric Liver Transplant
NCT01598987Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2012
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of everolimus in Liver transplant rejection, sponsored by Novartis. Primary endpoint: Change From Baseline in Estimated Glomerular Filtration Rate at Month 12. Started Oct 2012; status: completed.
02
Drugs
everolimus
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT01598987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01598987.